Jiangsu Aosaikang Pharmaceutical

Privately held: no public share price

Assets

(2 total)
2Total Assets
0Approved
2Phase 3 / Filed
0Phase 1–2 / Early
1Diseases
Showing 2 of 2 assets
Target & Modality
Phase 3
METSmall molecule
Non-Small Cell Lung Cancer
Phase 3
EGFR · EGFR T790M (resistant mutant, selective over wild-type EGFR)Small molecule
Non-Small Cell Lung Cancer

Upcoming events

(3 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (2)
June 2027 (1)
LimertinibPhase 1/2Solid Tumor
Est. primary completion 2027-06-30 · NCT07612137 · CT.gov ↗
What to watch
October 2027 (1)
ASKC202 + LimertinibPhase 3Locally Advanced or Metastatic NSCLC
Est. primary completion 2027-10-31 · NCT07109531 · CT.gov ↗
What to watch
2030 (1)
December 2030 (1)
ASKC202 + LimertinibPhase 3EGFR Activating Mutation, Non-Squamous Non-Small Cell Lung Cancer (NSCLC), MET Positive
Est. primary completion 2030-12-30 · NCT07897188 · CT.gov ↗
What to watch

See the full readout calendar ↗

Financial reports

No financial reports recorded.